pharmaceutical investing ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart maintains high levels of viral suppression in long-acting HIV treatment regimen 25 February
pharmaceutical investing U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer 24 February
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer 17 February
